Evidence map›Paper›PMID 41897683›Full record

ArticleDiagnostics (Basel, Switzerland)2026

Integrating Tumor Biology and Host Factors in mCRPC: The Prognostic Value of 'Time to Castration Resistance', Systemic Inflammation, and Comorbidity Burden in Patients Treated with Enzalutamide.

Seda Sali, Arife Ulaş, Sibel Oyucu Orhan, Sevgi Topçu, Muharrem Koçar, Mürsel Sali, Birol Ocak, Adem Deligönül, Türkkan Evrensel, Erdem Çubukçu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Seda SaliDepartment of Medical Oncology, University of Health Sciences, Bursa City Education and Research Hospital, Bursa 16250, Türkiye.ORCID 0000-0001-8575-5477
Arife UlaşDepartment of Medical Oncology, University of Health Sciences, Bursa City Education and Research Hospital, Bursa 16250, Türkiye.ORCID 0000-0003-2918-2592
Sibel Oyucu OrhanDepartment of Medical Oncology, University of Health Sciences, Bursa City Education and Research Hospital, Bursa 16250, Türkiye.ORCID 0000-0001-8217-3471
Sevgi TopçuDepartment of Medical Oncology, Tepecik Training and Research Hospital, İzmir 35120, Türkiye.ORCID 0000-0002-6626-0409
Muharrem KoçarDepartment of Medical Oncology, University of Health Sciences, Bursa City Education and Research Hospital, Bursa 16250, Türkiye.
Mürsel SaliDepartment of Medical Oncology, School of Medicine, Bursa Uludağ University, Bursa 16059, Türkiye.ORCID 0009-0007-2079-3350
Birol OcakDepartment of Medical Oncology, Bursa Yüksek İhtisas Training and Research Hospital, Bursa 16310, Türkiye.ORCID 0000-0001-7537-1699
Adem DeligönülDepartment of Medical Oncology, School of Medicine, Bursa Uludağ University, Bursa 16059, Türkiye.ORCID 0009-0001-3931-0191
Türkkan EvrenselDepartment of Medical Oncology, School of Medicine, Bursa Uludağ University, Bursa 16059, Türkiye.ORCID 0000-0002-9732-5340
Erdem ÇubukçuDepartment of Medical Oncology, School of Medicine, Bursa Uludağ University, Bursa 16059, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Charlson comorbidity indexenzalutamidemetastatic castration-resistant prostate cancerreal-world studiessystemic immune-inflammation indextime to castration resistance

Identifiers

PMID41897683
PMCPMC13025191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.